These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28884410)

  • 1. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
    Moyal L; Goldfeiz N; Gorovitz B; Rephaeli A; Tal E; Tarasenko N; Nudelman A; Ziv Y; Hodak E
    Invest New Drugs; 2018 Feb; 36(1):1-9. PubMed ID: 28884410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.
    Tarasenko N; Cutts SM; Phillips DR; Inbal A; Nudelman A; Kessler-Icekson G; Rephaeli A
    PLoS One; 2012; 7(2):e31393. PubMed ID: 22384017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Sung JJ; Ververis K; Karagiannis TC
    J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
    Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.
    Tarasenko N; Kessler-Icekson G; Boer P; Inbal A; Schlesinger H; Phillips DR; Cutts SM; Nudelman A; Rephaeli A
    Invest New Drugs; 2012 Feb; 30(1):130-43. PubMed ID: 20862515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
    Lopez AT; Bates S; Geskin L
    Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination.
    Koprinarova M; Botev P; Russev G
    DNA Repair (Amst); 2011 Sep; 10(9):970-7. PubMed ID: 21824827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
    Trager MH; Geskin LJ
    G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
    Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
    J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate.
    Nikolova T; Ensminger M; Löbrich M; Kaina B
    DNA Repair (Amst); 2010 Oct; 9(10):1050-63. PubMed ID: 20708982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Richon V; Ni X; Talpur R; Duvic M
    J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
    Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
    Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.